Table 2. Key takeaway messages from the survey.

No.	Key takeaway messages
BC, breast cancer; AET, adjuvant endocrine therapy; AI, aromatase inhibitor.
1	A high proportion of BC physician respondents would prescribe extended AET with AI beyond 5 years for postmenopausal females with BC.
2	For low-risk patients, 5 years of AET is acceptable, but a more experienced physician tends to take a more conservative approach and prescribes a longer duration of AET.
3	For intermediate- to high-risk patients, the optimal duration is unknown but 7−8 years of AET appears to be the “sweet spot”.
4	For high-risk patients, at least 10 years of AET may be warranted.
5	Intermittent letrozole can be considered for low-risk patients, especially for those with potentially poor adherence to extended AET.
6	Adjuvant chemotherapy should be prescribed to genomic high-intermediate risk females aged 50 years or younger regardless of the clinical risk classification.